CNKSR3 Antibody

What is CNKSR3 and why is it significant in research?

CNKSR3 (CNKSR Family Member 3, also known as CNK3, MAGI1, or membrane-associated guanylate kinase-interacting protein-like 1) is a scaffold protein involved in various signaling pathways. The protein has a predicted molecular weight of approximately 62 kDa and plays important roles in cellular signaling mechanisms . Research on CNKSR3 is significant because it contributes to our understanding of signal transduction pathways that may be relevant to both normal cellular functions and disease states. When designing experiments targeting CNKSR3, researchers should consider its expression patterns across different tissues and cell types to ensure appropriate experimental models are selected.

What types of CNKSR3 antibodies are available for research?

Multiple types of CNKSR3 antibodies are available for research purposes, including:

• Monoclonal antibodies (e.g., clone OTI1D7, 4A11) derived from mouse hosts

• Polyclonal antibodies from rabbit hosts

• Antibodies targeting different amino acid regions (AA 1-555, AA 301-555, AA 366-464)

• Unconjugated antibodies as well as those conjugated with tags like DyLight 550, FITC, HRP, or Biotin

The selection between monoclonal and polyclonal antibodies should be based on your experimental requirements. Monoclonal antibodies offer high specificity to a single epitope, making them ideal for applications requiring consistent results across experiments. Polyclonal antibodies recognize multiple epitopes, potentially providing stronger signals but with possible batch-to-batch variation.

What is the species reactivity of commonly available CNKSR3 antibodies?

The species reactivity of CNKSR3 antibodies varies by product. Based on the data:

• Most available CNKSR3 antibodies react with human samples

• Several antibodies also demonstrate cross-reactivity with mouse and rat samples

• Some antibodies are specifically tested for cross-reactivity (e.g., ABIN950108 has confirmed reactivity with human and mouse)

When selecting an antibody for your experiment, verify the validated species reactivity in the technical documentation. For novel applications or untested species, preliminary validation experiments are strongly recommended to confirm reactivity before proceeding with full-scale studies.

What are the validated applications for CNKSR3 antibodies?

CNKSR3 antibodies have been validated for various experimental applications:

When designing experiments, consider the specific application requirements and select antibodies validated for your intended use. For applications not explicitly validated, preliminary testing is essential to establish appropriate working conditions.

How should I optimize Western blot protocols for CNKSR3 detection?

For optimal Western blot detection of CNKSR3:

• Sample preparation: Use appropriate lysis buffers that preserve the native state of CNKSR3 and include protease inhibitors to prevent degradation.

• Loading control selection: Choose loading controls appropriate to your experimental context (e.g., GAPDH, β-actin, or tubulin).

• Antibody dilution: Start with the manufacturer's recommended dilution (typically 1:200-1:500 for primary antibodies) and optimize as needed.

• Band interpretation: The predicted molecular weight for CNKSR3 is approximately 62 kDa, which aligns with observed bands in validated Western blots . Discrepancies in observed molecular weight may occur due to post-translational modifications or splice variants.

• Controls: Include positive controls (e.g., HEK293T cells transfected with CNKSR3) and negative controls to validate specificity.

If working with mouse samples using mouse-derived antibodies, consider potential background interference and implement appropriate blocking strategies.

What factors should be considered when using CNKSR3 antibodies for immunohistochemistry?

For successful immunohistochemistry with CNKSR3 antibodies:

• Epitope retrieval: Heat-induced epitope retrieval using 10mM citric buffer (pH 6.0) at 120°C for 3 minutes has been validated for some CNKSR3 antibodies .

• Antibody dilution: A dilution of 1:150 is commonly recommended for IHC applications .

• Host species considerations: For mouse-derived antibodies used on mouse tissues, implement Mouse-on-Mouse blocking to reduce background signal. Products like PK-2200-NB or MP-2400-NB may be necessary .

• Validation controls: Include positive control tissues with known CNKSR3 expression. Adenocarcinoma of human endometrium has been used as a positive control for some CNKSR3 antibodies .

• Secondary antibody selection: Choose secondary antibodies with minimal cross-reactivity to the tissue being examined.

Careful optimization of these parameters is crucial for generating reliable and reproducible IHC results.

How do different CNKSR3 antibody clones compare in terms of epitope recognition and performance?

Different CNKSR3 antibody clones recognize distinct epitopes, which can affect experimental outcomes:

• Antibodies targeting the full-length protein (AA 1-555) provide broad epitope recognition

• Antibodies targeting specific regions (e.g., AA 301-555 or AA 366-464) offer targeted epitope recognition

• The monoclonal antibody clone OTI1D7 has been validated in multiple applications including WB and IHC

When selecting between different clones, consider:

• Epitope accessibility in your experimental context (native vs. denatured conditions)

• Known post-translational modifications that might affect epitope recognition

• Validation data specific to your application and experimental system

For critical experiments, comparing results with multiple antibodies recognizing different epitopes can provide stronger validation of findings and help identify potential false positives or negatives.

What are common troubleshooting strategies for non-specific binding or weak signal with CNKSR3 antibodies?

When encountering issues with CNKSR3 antibody experiments:

For non-specific binding:

• Increase blocking stringency using 5% BSA or 5% milk in TBS-T for Western blots

• For mouse-derived antibodies on mouse tissues, use specialized Mouse-on-Mouse blocking reagents

• Titrate primary antibody concentration to determine optimal signal-to-noise ratio

• Increase washing steps duration and volume

• Pre-absorb antibodies with non-relevant proteins if cross-reactivity is suspected

For weak signals:

• Optimize epitope retrieval conditions for IHC (temperature, buffer composition, and duration)

• Increase antibody concentration incrementally while monitoring background

• Extend primary antibody incubation time (overnight at 4°C instead of 1-2 hours)

• Use signal amplification systems appropriate for your detection method

• Verify sample integrity and target protein presence through alternative methods

Each of these troubleshooting approaches should be systematically implemented while maintaining appropriate controls to identify the source of experimental issues.

How can I validate the specificity of CNKSR3 antibody labeling in my experimental system?

Rigorous validation of CNKSR3 antibody specificity is crucial for reliable research outcomes:

• Multiple antibody approach: Compare results using antibodies that recognize different CNKSR3 epitopes

• Positive controls: Include samples with known CNKSR3 expression, such as:

  • HEK293T cells transfected with CNKSR3

  • Tissues with documented CNKSR3 expression

• Negative controls: Include:

  • Samples with CNKSR3 knockdown/knockout

  • Secondary antibody-only controls

  • Isotype controls for monoclonal antibodies

• Peptide competition assays: Pre-incubate the antibody with excess immunizing peptide to demonstrate binding specificity

• Alternative detection methods: Confirm findings using non-antibody-based methods like RNA-seq or RT-PCR to validate expression patterns

Proper documentation of these validation steps strengthens the reliability of your research findings and facilitates reproducibility.

What precautions should be taken when using mouse-derived CNKSR3 antibodies on mouse tissues?

Using mouse-derived antibodies on mouse tissues presents specific technical challenges:

• Background signal: Endogenous mouse immunoglobulins in the tissue can be recognized by anti-mouse secondary antibodies, creating high background.

• Solution approaches:

  • Implement Mouse-on-Mouse blocking reagents (e.g., PK-2200-NB, MP-2400-NB)

  • Use directly conjugated primary antibodies to eliminate the need for species-specific secondary antibodies

  • Consider secondary antibodies specifically designed to reduce background in mouse-on-mouse applications

  • Use alternative detection systems like biotin-streptavidin

• Controls: Include proper negative controls (secondary antibody only) to assess background levels

• Alternative approaches: Consider using CNKSR3 antibodies raised in species other than mouse, or using alternative detection methods where feasible

Documentation of these methodological considerations is essential when reporting research findings to ensure reproducibility.

How should CNKSR3 antibodies be stored and handled to maintain optimal performance?

Proper storage and handling of CNKSR3 antibodies is critical for maintaining their performance:

• Storage temperature:

  • Long-term storage: Most CNKSR3 antibodies should be stored at -20°C

  • Working aliquots: 4°C (for conjugated antibodies, store in the dark)

• Avoid freeze-thaw cycles:

  • Make small aliquots upon first thaw to minimize repeated freeze-thaw cycles

  • Document the number of freeze-thaw cycles for each aliquot

• Buffer considerations:

  • CNKSR3 antibodies are typically formulated in:

    • PBS with 1.0% BSA and 50% Glycerol

    • 50mM Sodium Borate for conjugated versions

  • All formulations contain preservatives (typically 0.02-0.05% sodium azide)

• Working dilutions:

  • Prepare fresh working dilutions on the day of experiment

  • Store any remaining diluted antibody according to manufacturer recommendations

• Expiration: Most primary antibodies are guaranteed for 1 year from receipt

Following these storage and handling guidelines will help ensure consistent experimental results and maximize antibody shelf-life.

What considerations are important when selecting conjugated CNKSR3 antibodies for multiplexed immunofluorescence experiments?

For multiplexed immunofluorescence experiments with conjugated CNKSR3 antibodies:

• Spectral compatibility:

  • DyLight 550 conjugates (Excitation = 562 nm, Emission = 576 nm) should be paired with fluorophores having minimal spectral overlap

  • Plan your panel to minimize bleed-through between channels

• Panel design considerations:

  • Pair high-abundance targets with dimmer fluorophores

  • Pair low-abundance targets with brighter fluorophores

  • Consider the relative expression levels of CNKSR3 and other targets

• Controls for multiplexed experiments:

  • Single-stained controls for each fluorophore

  • Fluorescence-minus-one (FMO) controls

  • Isotype controls for each conjugated antibody

• Titration:

  • Perform antibody titration experiments to determine optimal concentration

  • Optimize signal-to-noise ratio for each conjugated antibody individually

• Order of application:

  • Consider whether sequential or simultaneous application is optimal

  • Test for potential steric hindrance between antibodies targeting proximal epitopes

Careful optimization of these parameters will help ensure reliable results in complex multiplexed experiments.

How should inconsistencies in CNKSR3 antibody results between different experimental techniques be resolved?

When faced with inconsistent results between different experimental techniques:

• Evaluate antibody validation status for each technique:

  • Confirm antibodies are validated for each specific application

  • Review published literature using the same antibodies and techniques

• Consider technical differences:

  • Western blot detects denatured proteins while IHC/IF may detect native conformations

  • Epitope accessibility varies between techniques

  • Fixation methods in IHC/IF may mask or alter epitopes

• Systematic validation approach:

  • Test multiple antibodies recognizing different epitopes

  • Use complementary non-antibody techniques (mRNA analysis, mass spectrometry)

  • Conduct knockdown/knockout experiments to confirm specificity

• Quantitative analysis:

  • Apply appropriate quantification methods for each technique

  • Use statistical approaches suitable for the data type

  • Document all analysis parameters for reproducibility

• Integrate results:

  • Develop a consensus interpretation based on multiple lines of evidence

  • Acknowledge limitations and discrepancies in your findings

  • Consider biological explanations for apparent technical inconsistencies

This systematic approach helps build a more complete and reliable understanding of CNKSR3 biology.

What are the best practices for quantifying CNKSR3 expression in Western blots and immunohistochemistry?

For accurate quantification of CNKSR3 expression:

In Western blot analysis:

• Include a standard curve of recombinant CNKSR3 protein for absolute quantification

• Use appropriate loading controls (GAPDH, β-actin, total protein stains)

• Ensure signal is within the linear range of detection

• Apply appropriate normalization methods

• Use technical and biological replicates (minimum n=3)

• Apply appropriate statistical tests for comparing expression levels

In immunohistochemistry:

• Use standardized scoring systems (H-score, Allred score, or similar)

• Consider automated image analysis software for unbiased quantification

• Assess both staining intensity and percentage of positive cells

• Include positive and negative control tissues in each run

• Implement blinded scoring by multiple observers when possible

• Document specific regions analyzed (especially for heterogeneous tissues)

For both methods, detailed documentation of all quantification parameters is essential for reproducibility and meaningful comparison between studies.

How can CNKSR3 antibodies be utilized in investigating protein-protein interactions and signaling pathways?

CNKSR3 antibodies can be powerful tools for studying protein interactions and signaling:

• Co-immunoprecipitation (Co-IP):

  • Use CNKSR3 antibodies validated for IP applications to pull down CNKSR3 and associated proteins

  • Analyze pulled-down complexes by Western blot or mass spectrometry

  • Include appropriate controls (IgG control, lysate input)

  • Consider cross-linking approaches for transient interactions

• Proximity ligation assay (PLA):

  • Combine CNKSR3 antibodies with antibodies against putative interacting partners

  • Visualize protein-protein interactions in situ with subcellular localization

  • Validate interactions using multiple antibody pairs

• Immunofluorescence co-localization:

  • Use CNKSR3 antibodies in combination with markers for cellular compartments or potential interacting proteins

  • Apply rigorous co-localization analysis methods (Pearson's coefficient, Manders' coefficient)

  • Consider super-resolution microscopy for detailed co-localization studies

• Functional studies:

  • Combine antibody-based detection with kinase inhibitors or other pathway modulators

  • Monitor changes in CNKSR3 localization, phosphorylation, or interaction partners following pathway stimulation or inhibition

  • Correlate biochemical findings with functional outcomes

These approaches provide complementary insights into CNKSR3's role in signaling networks and cellular processes.

How can CNKSR3 antibodies be used in conjunction with advanced imaging techniques?

CNKSR3 antibodies can be integrated with cutting-edge imaging technologies:

• Super-resolution microscopy:

  • Use directly conjugated CNKSR3 antibodies (e.g., DyLight 550 conjugates) for STORM, PALM, or STED microscopy

  • Achieve nanoscale resolution of CNKSR3 localization and organization

  • Combine with other protein markers for detailed spatial relationship analysis

• Live-cell imaging:

  • Develop cell-permeable CNKSR3 antibody fragments or nanobodies

  • Monitor dynamic changes in CNKSR3 localization in response to stimuli

  • Combine with fluorescent biosensors to correlate CNKSR3 dynamics with signaling activities

• Expansion microscopy:

  • Use CNKSR3 antibodies in protocols for physical expansion of specimens

  • Achieve super-resolution-like results with conventional microscopes

  • Examine detailed subcellular localization patterns

• Correlative light and electron microscopy (CLEM):

  • Locate CNKSR3 by fluorescence and examine ultrastructural context by EM

  • Use gold-conjugated secondary antibodies for immuno-EM localization

  • Integrate molecular specificity with ultrastructural information

These advanced imaging approaches offer unprecedented insights into CNKSR3 biology at the subcellular level.

What are the considerations for using CNKSR3 antibodies in single-cell analysis techniques?

When incorporating CNKSR3 antibodies in single-cell analyses:

• Mass cytometry (CyTOF):

  • Conjugate CNKSR3 antibodies with rare earth metals

  • Include in panels with up to 40 other protein markers

  • Optimize signal-to-noise ratio through careful titration

  • Develop appropriate analysis pipelines for high-dimensional data

• Single-cell Western blotting:

  • Adapt CNKSR3 antibody dilutions for microfluidic single-cell Western platforms

  • Validate specificity in the single-cell context

  • Include appropriate controls for accurate quantification

  • Develop normalization strategies for cell-to-cell comparisons

• Imaging mass cytometry:

  • Use metal-conjugated CNKSR3 antibodies for spatial analysis in tissue sections

  • Combine with other markers to characterize CNKSR3-expressing cells in their tissue context

  • Apply appropriate segmentation and analysis algorithms

• Microfluidic immunoassays:

  • Adapt CNKSR3 antibody protocols for microfluidic platforms

  • Consider surface immobilization strategies for capture antibodies

  • Validate assay sensitivity and specificity at the single-cell level

These emerging technologies enable analysis of CNKSR3 expression and function with unprecedented resolution at the single-cell level.

How might CNKSR3 antibodies contribute to understanding disease mechanisms and potential therapeutic targets?

CNKSR3 antibodies can advance disease research through:

• Biomarker development:

  • Validate CNKSR3 expression patterns in normal versus disease tissues

  • Correlate expression with disease progression or therapeutic response

  • Develop standardized IHC protocols for potential diagnostic applications

• Mechanistic studies:

  • Investigate CNKSR3's role in signaling pathways implicated in disease

  • Map interaction partners in normal versus disease states

  • Identify potential dysregulation of CNKSR3 function or localization in pathological conditions

• Therapeutic target validation:

  • Use antibodies to monitor CNKSR3 levels following experimental interventions

  • Develop blocking antibodies to disrupt specific CNKSR3 interactions

  • Evaluate effects of CNKSR3 modulation on disease-relevant cellular phenotypes

• Theranostic applications:

  • Explore potential for antibody-drug conjugates targeting CNKSR3

  • Develop imaging agents based on CNKSR3 antibodies for potential diagnostic applications

  • Investigate tissue-specific expression patterns to assess potential on-target effects

By applying CNKSR3 antibodies in these contexts, researchers can build a more comprehensive understanding of CNKSR3's potential contributions to disease pathogenesis and treatment.